FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Gibbs Michael Terrence 2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [ TTOO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
General Counsel
(Last)         (First)         (Middle)
101 HARTWELL AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)
2/21/2021
(Street)
LEXINGTON, MA 02421
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  2/21/2021    M    10000  A  (1) 72627 (2) D   
Common Stock  2/23/2021    S(3)    7280  D $2.06  65347  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units   (1) 2/21/2021    M        10000    (4)  (4) Common Stock  10000  $0.00  10000  D   

Explanation of Responses:
(1)  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
(2)  Includes 714 shares acquired under the Issuer's employee stock purchase plan ("ESPP") on May 15, 2019, 1,132 shares acquired under the ESPP on November 15, 2019 and 2 shares acquired under the ESPP on May 15, 2020.
(3)  The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2018.
(4)  On February 21, 2019 the reporting person was granted 30,000 RSU's that vest in three equal annual installments beginning on February 21, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Gibbs Michael Terrence
101 HARTWELL AVENUE
LEXINGTON, MA 02421


General Counsel

Signatures
/s/ John Sprague, Attorney-in-fact 2/23/2021
**Signature of Reporting Person Date